Company Overview and News
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
July marks the ninth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $640.87.
SOJA GIS XOM SKT LTC OPRF SEP BPL MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI ETP ORI WPC SPG ADM
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
Document UNITED STATES
Old Republic International (ORI - Free Report) just came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.
IBCP IBTX ORI INDB
2018-07-19 seekingalpha - 2
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT WBA ENB OPRF JCI HSY ABBV MMM POL MO DUKH GD TRV MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10-24; Challengers have 5-9. WallStar selections all show .5% or higher price target upsides.
PM HMLP ETE GLOP ENB ANDX PBFX DKL SUN EBBNF MO ENBBF PEGI TLP NRZ SRLP ENB TCP ORI SIR PEG
June marks the eighth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $676.96.
SOJA GIS XOM IDCC SKT LTC OPRF BPL SEP COP MIC CINF AAPL CAH EMR BBT SO TLP WLK O MSB OZRK CMI ETP HP ORI SPG WPC ADM
39 of 91 Dividend Achievers (10 or more years of higher dividends) were tagged "safer" because they showed positive annual returns, and free cash flow yields greater than dividend yields 7/11/18.
HEP WHG O OPRF CMI VZA ORI CVX LAZ VZ WELL WPC QCOM NHI LEG NNN IVZ
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET